Previous 10 | Next 10 |
home / stock / okyo / okyo articles
Over the past twenty days of trading, OKYO Pharma Limited (NASDAQ: OKYO), from September 06, 2023 to October 03, 2023 there is a potential Short S...
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 111% to $0.4000. Avinger, Inc. (NASDAQ: AVGR) surged 63.2% to $6.75 amid the company announcing...
Gainers T2 Biosystems, Inc. (NASDAQ: TTOO) shares rose 44.4% to $0.4003 in pre-market trading. T2 Biosystems said it issued inducement awards to f...
Thursday witnessed a widespread rally across the spectrum of risk markets, with both equities and commodities surging in response to a slew of econ...
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from ...
LONDON and NEW YORK, Sept. 14, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bi...
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 43.3% to $1.29 in pre-market trading. Avalo Therapeutics, Inc. (NASDAQ: AVTX) sha...
With inflation data in the rearview mirror, traders could be prepping to resume buying ways, with stock index futures pointing to a higher opening ...
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares rose 38.7% to $0.1713 in pre-market trading. Shares of Avalo Therapeutics jumped over 45% on Tuesday...
News, Short Squeeze, Breakout and More Instantly...
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024 OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain ...
Encouraging 68% improvement in responder rate results from patients who achieved both the conjunctival staining “sign” and ocular pain “symptom” endpoints from the 240 patient Phase 2 Dry Eye Disease (DED) trial Conjunctival staining and ocular pain represe...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...